55276-42-1

Basic information

• Product Name: 2-benzylbenzyl bromide
• Synonyms: 2-benzylbenzyl bromide
• CAS NO: 55276-42-1
• Molecular Weight: 261.161
• Mol File: 55276-42-1.mol

Chemical Properties

• CAS DataBase Reference: 2-benzylbenzyl bromide(CAS DataBase Reference)
• NIST Chemistry Reference: 2-benzylbenzyl bromide(55276-42-1)
• EPA Substance Registry System: 2-benzylbenzyl bromide(55276-42-1)

Safety Data

• Hazardous Substances Data: 55276-42-1(Hazardous Substances Data)

Upstream product

• 1586-00-1 2-(benzyl)benzyl alcohol 
• 612-35-1 2-Benzylbenzoic acid 
• 6962-60-3 2-benzyl-benzoic acid methyl ester 
• 17100-66-2 2-(tetrahydropyranyloxy)methylbromobenzene 
• 18982-54-2 o-bromobenzyl alcohol 
• 100-39-0 benzyl bromide 
• 32832-95-4 2-benzylbenzaldehyde 
• 40138-16-7 2-formylbenzene boronic acid 
• 141938-57-0 2-(2-Benzyl-benzyloxy)-tetrahydro-pyran 
• 85-52-9 2-Benzoylbenzoic acid 

Downstream Products

• 1586-03-4 2-(2-benzylphenyl)acetonitrile 
• 88689-60-5 2,2'-dibenzyl-bibenzyl 
• 1586-02-3 2-Aethoxymethyl-diphenylmethan 
• 36374-49-9 2-(2-benzylphenyl)acetic acid 
• 713-36-0 2-benzyltoluene 
• 716-78-9 1-benzyl-2-(deuteriomethyl)benzene 
• 96217-05-9 Bis-<2-benzyl-benzyl>-aether 
• 1586-28-3 Diphenylmethan-2-carbonsaeure-(2-benzyl-benzylester) 
• 6196-39-0 1-(2-benzylphenyl)-N,N-dimethylmethanamine 
• 141938-55-8 2-[2-(2-Benzyl-benzyl)-benzyloxy]-tetrahydro-pyran 
• 69007-90-5 2-(2-Benzyl-benzyl)-malonic acid diethyl ester 
• 1962-37-4 4-benzyl-2,3-dihydro-1H-inden-1-one 
• 2327-09-5 5[2'-(benzyl)phenyl]propionic acid 
• 1253186-22-9 2,6-difluoro-N-(1-{[2-(phenylmethyl)phenyl]methyl}-1H-pyrazol-3-yl)benzamide 

Relevant articles and documents

Synthesis of Benzoazepine Derivatives via Azide Rearrangement and Evaluation of Their Antianxiety Activities

A new synthetic method for the construction of benzoazepine analogues has been developed employing ortho-arylmethylbenzyl azide derivatives as precursors using an azide rearrangement reaction. In this work, 14 benzoazepine compounds were successfully synthesized in moderate to excellent yields. All synthetic benzoazepines were evaluated for their cytotoxicity against normal human kidney cell line (HEK cell). The results showed that compound 18c had the lowest cytotoxicity (IC50 = 65.68 μM) among tested compounds, which was comparable with the antianxiety drug diazepam (IC50 = 87.90 μM). Based on the cytotoxicity results, five benzoazepine analogues (compounds 18c, 18h, 18j, 18n, and 18p) were selected to determine the antianxiety effect on stressed rats using elevated plus maze (EPM) and open field test (OFT) methods. Interestingly, compound 18c showed better anxiolytic activity than diazepam without a sedative effect by showing superior hyperlocomotor activity. Therefore, this discovery could pave the way for drug development to treat patients with anxiety disorder.

Method for preparing coupling arene from aryl halide by ionizing, discharging and coupling

The invention discloses a method for preparing coupling arene from aryl halide by ionizing, discharging and coupling. The method comprises the following steps: placing a magnetic stirrer into a three-necked flask and adding aryl halide occupying 1/2 flask, thereby finishing the assembling of an ionizing reaction device; placing the ionizing reaction device into an oil bath pan, introducing inert gas into a reaction system, removing air from the reaction system, starting stirring and heating in the oil bath pan to make aryl halide flow back, and meanwhile, introducing water into a ball-shaped condensation pipe for cooling; starting a high-voltage power generator, and introducing powerful arc generated into the three-necked flask through a metal electrode, thereby ionizing and decomposing aryl halide steam and generating a coupling arene compound; stopping ionizing and heating when solids are separated or the backflow of aryl halide is slowed in a round-bottom flask, and then ending the reaction; recrystallizing or performing reduced pressure distillation purification on the coupling arene product in the flask, thereby acquiring the coupling arene product. The method disclosed by the invention has the advantages of low cost, high efficiency, environmental protection, and the like.

PYRAZOLE COMPOUNDS ACTING AGAINST ALLERGIC, INFLAMMATORY AND IMMUNE DISORDERS

The present invention relates to pyrazole amide derivatives pharmaceutical compositions containing these compounds and to their use in therapy.

Substituted imidazoline-2,4-diones, process for preparation thereof, medicaments comprising these compounds and use thereof

The invention relates to compounds of formula (I) wherein the groups R and R′, A, D, E, G, L, p and R1 to R10 have the stated meanings and to their physiologically compatible salts. Said compounds are suitable, for example, as anti-obesity drugs.

N-PYRAZOLYL CARBOXAMIDES AS CRAC CHANNEL INHIBITORS

The present invention relates to amide compounds, processes for their preparation, pharmaceutical compositions containing these compounds and to their use in the treatment of disorders, conditions or disorders such as allergic disorders, inflammatory disorders and disorders of the immune system.

SPIRO COMPOUNDS USEFUL AS ANTAGONISTS OF THE H1 RECEPTOR

The invention provides a compound of formula (I) or a pharmaceutically acceptable salt thereof, for treating diseases and conditions of the central nervous system (CNS), in particular sleep disorders.

Tricyclic alkylamides as melatonin receptor ligands with antagonist or inverse agonist activity

This work reports the design and synthesis of novel alkylamides, characterized by a dibenzo[a,d] cycloheptene nucleus, as melatonin (MLT) receptor ligands. The tricyclic scaffold was chosen on the basis of previous quantitative structure-activity studies on MT1 and MT2 antagonists, relating selective MT2 antagonism to the presence of an aromatic substituent out of the plane of the MLT indole ring. Some dibenzo seven-membered structures were thus selected because of the noncoplanar arrangement of their benzene rings, and an alkylamide chain was introduced to fit the requirements for MLT receptor binding, namely, dibenzocycloheptenes with an acylaminoalkyl side chain at position 10 and dibenzoazepines with this side chain originating from the nitrogen atom bridging the two phenyl rings. Binding affinity at human cloned MT1 and MT2 receptors was measured by 2[125I] iodomelatonin displacement assay and intrinsic activity by the GTPγS test. The majority of the compounds were characterized by higher affinity at the MT2 than at the MT 1 receptor and by very low intrinsic activity values, thus confirming the importance of the noncoplanar arrangement of the two aromatic rings for selective MT2 antagonism. Dibenzocycloheptenes generally displayed higher MT1 and MT2 affinity than dibenzoazepines. N-(8-Methoxy-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-10-ylmethyl)propionamide (4c) and -butyramide (4d) were the most selective MT2 receptor antagonists of the series, with MT2 receptor affinity comparable to that of melatonin and as such among the highest reported in the literature for MLT receptor antagonists. The acetamide derivative 4b produced a noticeable reduction of GTPγS binding at MT2 receptor, thus being among the few inverse agonists described.

Substituted tricyclics

A class of novel tricyclics is disclosed together with the use of such compounds for inhibiting sPLA2mediated release of fatty acids for treatment of conditions such as septic shock.

Substituted aryl and heteroaryl compounds as E-type prostaglandin antagonists

This invention relates to substituted and unsubstituted ???(aryl- and heteroaryl-) alkyl-, alkyloxy-, alkylthio-, oxo-, thio-, and alkylamino!- heteroaryl and aryl!- alkylamino-, aminoalkyl-, alkyloxy-, and alkylthio!- aryl and heteroaryl compounds of the formula STR1 and pharmaceutically acceptable salts thereof, which are useful as antagonists of the pain enhancing effects of E-type prostaglandins, to processes for the preparation of such compounds, to pharmaceutical compositions comprising such compounds, and to methods for treating pain comprising the administration of such compounds.

Biscyclophanes. Part 1: Synthesis of a Common-nuclear Bisorthocyclophane, First Member of a New Family of Cyclophanes

Synthesis of new orthocyclophane hosts has been investigated by the acid-catalysed intramolecular Friedel-Crafts cycloalkylation of terminal benzylbenzylic alcohols that bear repeating benzyl chains.Treatment of 2-(2-benzylbenzyl)benzyl alcohol 6 with concentrated sulfuric acid in acetic acid medium gave rise to a cyclisation product, orthocyclophane 2.Similar cyclisation behaviour was observed under the same reaction conditions by the use of diterminal benzylbenzylic diols, which provided a common-nuclear bisorthocyclophane.Treatment of a solution of either the α,ω-benzylic diols 1,3-bisbenzyl>benzene 16 in acetic acid or the 1,4-isomer 20 in acetic acid-dimethyl sulfoxide with concentrated sulfuric acid provided heptacyclo3,19.05,10.012,17.023,28.030,35>hexatriaconta-1(21),2,5(10),6,8,12(17),13,15,19,23(28),24,26,30(35),31,33-pentadecaene 3 which is the first member of a family of novel biscyclophanes.